David A Barbie


Affiliation: Massachusetts General Hospital
Country: USA


  1. Jenkins R, Thummalapalli R, Carter J, Cañadas I, Barbie D. Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. Annu Rev Med. 2017;: pubmed publisher
    ..Expected final online publication date for the Annual Review of Medicine Volume 69 is January 29, 2018. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates...
  2. Jenkins R, Aref A, Lizotte P, Ivanova E, Stinson S, Zhou C, et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018;8:196-215 pubmed publisher
    ..i>Cancer Discov; 8(2); 196-215. ©2017 AACR.See related commentary by Balko and Sosman, p. 143See related article by Deng et al., p. 216This article is highlighted in the In This Issue feature, p. 127. ..
  3. Van Allen E, Golay H, Liu Y, Koyama S, Wong K, Taylor Weiner A, et al. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res. 2015;3:855-63 pubmed publisher
    ..These findings suggest that genomic alterations that deregulate cytokine receptor signal transduction could contribute to PD-L1 activation and engagement of the PD-1 immune checkpoint in lung cancer. ..
  4. Terai H, Kitajima S, Potter D, Matsui Y, Quiceno L, Chen T, et al. ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2018;78:1044-1057 pubmed publisher
    ..i>Cancer Res; 78(4); 1044-57. ©2017 AACR. ..
  5. Sundararaman S, Barbie D. Tumor cGAMP Awakens the Natural Killers. Immunity. 2018;49:585-587 pubmed publisher
    ..2018) reveal that tumor cells produce 2'3'-cGAMP, which activates the STING pathway in non-tumor cells and leads to type I IFN production and the priming of natural killer cells for tumor rejection. ..
  6. Kitajima S, Ivanova E, Guo S, Yoshida R, Campisi M, Sundararaman S, et al. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. Cancer Discov. 2018;: pubmed publisher
    ..These results begin to uncover the key underlying mechanism and identify strategies to restore STING expression, with important therapeutic implications because mitochondrial dysfunction is an obligate component of this tumor subtype. ..
  7. Kitajima S, Asahina H, Chen T, Guo S, Quiceno L, Cavanaugh J, et al. Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS. Cancer Cell. 2018;34:439-452.e6 pubmed publisher
    ..Using potent and selective TBK1 and BET inhibitors we further develop an effective therapeutic strategy with potential translatability to the clinic. ..
  8. Barbie D, Spira A, Kelly K, Humeniuk R, Kawashima J, Kong S, et al. Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure. Clin Lung Cancer. 2018;19:e853-e859 pubmed publisher
    ..The additional use of momelotinib with trametinib does not improve on the activity of single-agent trametinib in KRAS-mutated NSCLC on the basis of historic data. ..
  9. Cañadas I, Thummalapalli R, Kim J, Kitajima S, Jenkins R, Christensen C, et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018;24:1143-1150 pubmed publisher
    ..Together, these data unveil a subclass of ERVs whose derepression triggers pathologic innate immune signaling in cancer, with important implications for cancer immunotherapy. ..

More Information


  1. Yang S, Imamura Y, Jenkins R, Cañadas I, Kitajima S, Aref A, et al. Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. Cancer Immunol Res. 2016;4:520-30 pubmed publisher
    ..These findings could contribute to the dual role of autophagy in oncogenesis and have important consequences for its therapeutic targeting. Cancer Immunol Res; 4(6); 520-30. ©2016 AACR. ..
  2. Kitajima S, Thummalapalli R, Barbie D. Inflammation as a driver and vulnerability of KRAS mediated oncogenesis. Semin Cell Dev Biol. 2016;58:127-35 pubmed publisher
  3. Kitajima S, Barbie D. RASA1/NF1-Mutant Lung Cancer: Racing to the Clinic?. Clin Cancer Res. 2018;24:1243-1245 pubmed publisher
    ..i>Clin Cancer Res; 24(6); 1243-5. ©2018 AACRSee related article by Hayashi et al., p. 1436. ..
  4. Jenkins R, Barbie D. Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma. Cancer Discov. 2017;7:799-801 pubmed publisher
    ..i>Cancer Discov; 7(8); 799-801. ©2017 AACR.See related article by Eskiocak et al., p. 832. ..